← Peptide library
Fat Loss

Retatrutide

Research overview and evidence limits

The investigational triple agonist combining appetite control with an energy expenditure signal.

Measurement example only. The values below are not a recommended dose or treatment schedule.

Vial
10 mg
BAC Water
2 mL
Dose
2 mg
Units on 1 mL
40
Note: 2 mg is a measurement example only. Retatrutide is investigational with no approved starting dose or treatment schedule.

Also sold as

Research chemical vendors can't legally label products with the real name, so Retatrutide often appears under coded SKUs. If you're shopping and see any of these, it's the same compound:

  • 3R· Common shorthand
  • Branch-3R· Branch Peptides
  • GLP-3
  • GLP3
  • Triple-R
  • Reta
  • LY-3437943

Codes shown are for identification only.

Retatrutide vial

Your draw

40 units · 2 mg
00.0100.1200.2300.3400.4500.5600.6700.7800.8900.91001.0DRAW TO 40u100-UNIT · 1 mL SYRINGE40u
On a standard 100 unit / 1 mL insulin syringe.

Research evidence

Evidence level
Human clinical research
Last reviewed

Investigational; not FDA approved as of this review.

Phase 3 results now supplement the earlier Phase 2 trial. TRIUMPH-2 studied adults with type 2 diabetes and obesity or overweight for 80 weeks; Lilly reported mean weight reduction of 20.8% in the 12 mg group. This is a study result, not a recommended dose or a prediction for an individual. Different populations, durations and analyses prevent simple comparisons with other trials. Trial products are not interchangeable with research vendor products.

Sources

What it actually is

Retatrutide is a once weekly investigational medicine that activates GLP-1, GIP, and glucagon receptors. GLP-1 and GIP affect appetite, insulin response, and blood glucose; the glucagon component may also increase energy expenditure. A 48 week Phase 2 obesity trial reported about 24% mean weight reduction in the highest dose group. New Phase 3 data include TRIUMPH-2: in adults with type 2 diabetes and obesity or overweight, Lilly reported 20.8% mean weight reduction in the 12 mg group over 80 weeks (September 2026). These populations and durations differ; the figures are not a ranking, a recommended dose or a guarantee. Retatrutide is not currently an approved prescription medicine, and its long term benefit risk profile is still being studied.

Retatrutide remains investigational. Published trials used gradual dose escalation to improve tolerability. Nausea, vomiting, diarrhea, constipation, and increased heart rate have been reported. It should not be described as an approved alternative to semaglutide or tirzepatide.

Why people use it

  • Interest in Phase 3 obesity and diabetes results, with study population and duration kept explicit
  • Research into obesity, insulin resistance, and reduction of excess liver fat
  • Once weekly action across three metabolic receptor pathways
  • Important distinction: trial results come from controlled investigational use, not unverified research products

Educational only · Not a vendor claim

How it works

Activates GLP-1, GIP, and glucagon receptors in one investigational molecule. The first two pathways influence satiety and glucose regulation, while glucagon receptor activity may raise energy expenditure and fat oxidation.

Research findings

  • Phase 2 obesity trial: about 24% mean weight reduction at 48 weeks in the highest dose group
  • Phase 3 TRIUMPH-2: 20.8% mean weight reduction at 80 weeks in the 12 mg group with type 2 diabetes and obesity or overweight (Lilly, September 2026)
  • Promising reductions in waist circumference and cardiometabolic risk markers
  • Research signal for reducing excess liver fat
  • Once weekly pharmacology

Response and uncertainty

  • Appetite and food intake may fall substantially
  • Weight change builds over months rather than days
  • GI tolerance can change after each escalation
  • Resting heart rate may increase

Pros

  • Three complementary metabolic targets
  • Phase 3 obesity and diabetes findings now available
  • Controlled studies with defined populations and follow up
  • Potential beyond appetite reduction alone

Cons

  • Not approved for routine clinical use
  • No mature long term safety record
  • Trial percentages are not directly comparable across different studies
  • Unverified products do not replicate clinical-trial quality controls

Side effects to know

  • Nausea or vomiting
  • Diarrhea or constipation
  • Reduced appetite and fatigue
  • Increased heart rate
  • Potential class risks involving gallbladder, pancreas, dehydration, and severe GI symptoms

Research context

Understanding triple agonist researchComparing emerging obesity therapiesReviewing clinical-trial evidence, not self-treatment

Educational summary · Not medical advice · Discuss with a qualified clinician

Stacking partners

Commonly discussed combinations

Community combinations are not proven treatment recommendations. Different proposed mechanisms do not establish effectiveness, compatibility or safety when combined.

Read the safety guide before stacking.

Was this page helpful?

The reconstitution math

  1. 1Reconstitute the 10 mg vial with 2 mL of bacteriostatic water. Tilt — don't shake.
  2. 2Concentration becomes 5,000 mcg/mL (5 mg/mL).
  3. 3For a 2 mg dose, draw 0.400 mL — that's 40 units on a 1 mL insulin syringe.
  4. 4One vial gives you approximately 5 doses.

Reminder: on a U-100 insulin syringe, 100 units = 1 mL. This example converts a selected amount into volume; it does not determine a safe dose, injection route or treatment plan.

Dose log

Dose logging is available for signed in users. Track today's dose and notes for Retatrutide.

Alert me when Retatrutide drops in price

We track Branch Peptides pricing every day. Tell us where to reach you and we'll flag the next price drop or restock.

Price and restock alerts only, plus the occasional new peptide release. Unsubscribe whenever.

Free printable for Retatrutide

Mixing ratios, units to draw and storage basics — one page, no strings.

One email at a time. Don't worry, we won't spam your inbox. Unsubscribe whenever. We never sell your address.

Trusted source
Buy Retatrutide at Branch Peptides

Use code ANYPEPTIDES15 for 15% off your order.

Discount may end or change without notice.

Shop on BranchPeptides.com
Shop Retatrutide
Code ANYPEPTIDES15 · 15% off
Shop now
Language